EUVIMEDEUVIMED entdecken
Open Access

Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022

Emily Glidden, R Matthew Gladden, Chris Dion, Meghan B Spyres, Puja Seth, Kim Aldy, Desiree Mustaquim, Toxicology Investigators Consortium (ToxIC)

MMWR. Morbidity and Mortality Weekly Report · 2024

DOI: 10.15585/mmwr.mm7329a2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2024. Verfasst von Emily Glidden und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Oxycodone, Registries, Counterfeit Drugs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Availability of counterfeit prescription pills (counterfeit pills) containing illegally made fentanyl, including counterfeit M-30 oxycodone (counterfeit M-30) pills, has risen sharply in the United States and has been increasingly linked to overdose deaths. In 2023, approximately 115 million counterfeit pills were seized in U.S. High Intensity Drug Trafficking Areas. However, clinical data on counterfeit pill-related overdoses are limited. Medical toxicology consultations during 2017-2022 from one U.S. Census Bureau Western Region hospital participating in the Toxicology Investigators Consortium Core Registry were analyzed. A total of 352 cases suspected to involve counterfeit M-30 pills, including 143 (40.6%) cases of fentanyl exposure and 209 (59.4%) cases of acute withdrawal were identified; consultations increased from three in 2017, to 209 in 2022. Patients aged 15-34 years accounted for 95 (67.4%) exposure cases. Among all patients with exposures, 81.1% were hospitalized, 69.0% of whom were admitted to an intensive care unit. Additional substances were detected in 131 (91.6%) exposures. Providing outreach to younger persons misusing prescription pills, improving access to and distribution of harm reduction tools including fentanyl test strips and naloxone, and promoting linkage of persons treated for overdose in hospitals to harm reduction and substance use treatment services are strategies to reduce morbidity associated with use of counterfeit M-30.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxycodoneRegistriesCounterfeit DrugsHumansAdultAdolescentYoung AdultMaleUnited StatesFemaleMiddle AgedSubstance Withdrawal SyndromeCensusesAgedDrug OverdoseChildHospitals

Substanzen

OxycodoneCounterfeit Drugs

Zitieren

APA

Glidden, E., Gladden, R. M., Dion, C., Spyres, M. B., Seth, P., Aldy, K., Mustaquim, D., & Toxicology Investigators Consortium (ToxIC) (2024). Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7329a2

Vancouver

Glidden E, Gladden RM, Dion C, Spyres MB, Seth P, Aldy K, et al. Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022. MMWR. Morbidity and Mortality Weekly Report. 2024. doi:10.15585/mmwr.mm7329a2

BibTeX
@article{Glidden2024,
  author = {Glidden, Emily and Gladden, R Matthew and Dion, Chris and Spyres, Meghan B and Seth, Puja and Aldy, Kim and Mustaquim, Desiree and Toxicology Investigators Consortium (ToxIC), Toxicology Investigators Consortium (ToxIC)},
  title = {Suspected Counterfeit M-30 Oxycodone Pill Exposures and Acute Withdrawals Reported from a Single Hospital — Toxicology Investigators Consortium Core Registry, U.S. Census Bureau Western Region, 2017–2022},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  year = {2024},
  doi = {10.15585/mmwr.mm7329a2}
}
Kostenlos starten →